Red Queen Bio

Based in the US, Red Queen Bio develops advanced biosecurity solutions utilizing artificial intelligence to address biological threats through innovative methodologies and strategic partnerships. Red Queen Bio specializes in the development of biosecurity technologies. Founded by a team with a focus on leveraging AI in biodefense, their headquarters is located in the United States. The company recently raised USD 15 mn in a Seed funding round on November 14, 2025, led by OpenAI, with other investors including Cerberus Capital Management, Fifty Years, and Halcyon Ventures.

This funding represents the total amount raised by the company to date. Red Queen Bio specializes in developing advanced biosecurity solutions that leverage artificial intelligence to counteract biological threats. Their core offerings include a countermeasure design pipeline utilizing leading AI models, lab automation, and reinforcement learning to create medical countermeasures against AI-enabled biothreats. The company collaborates with frontier laboratories to pre-build defenses that are scalable with computational resources, facilitating rapid responses to emerging biological risks.

Their services are targeted at various stakeholders in the biopharma industry, including government entities and private sector players focused on biodefense, with an operational focus in the United States and international markets. Red Queen Bio has initiated its revenue model with a USD 15 mn Seed funding round led by OpenAI, alongside participation from Cerberus Capital Management, Fifty Years, and Halcyon Ventures. The company’s business transactions are structured around partnerships with governmental entities and biopharma companies. Revenue generation occurs through investments in cooperative projects that align with client objectives, focusing on creating tailored defensive solutions.

Pricing structures for specific products and services are defined through direct negotiations, reflecting the bespoke nature of their offerings, while the company operates as a Public Benefit Corporation, prioritizing its mission in financial arrangements with stakeholders. In November 2025, Red Queen Bio PBC raised USD 15 mn in Seed funding, which will be used to combine advanced AI models with laboratory experiments to identify, assess, and mitigate emerging biosecurity risks before they can be exploited by malicious actors. The company aims to develop new products focused on enhancing biosecurity measures, targeting expansion into international markets over the next few years, further promoting robust defense infrastructures against biological threats.